Diversity Maturity Model for Organizational-Level Strategies
Access to Clinical Trials
CTTI Publication Investigates Organizational Practices to Promote Diversity and Inclusion in Clinical Trials
A new CTTI publication, published in the Journal of Clinical Pharmacology & Therapeutics, investigates organizational-level practices for enhancing diversity and inclusion in clinical trials as one component of advancing health equity and improving health outcomes. When clinical trial participants do not reflect the populations that will use the medical product, it can limit our understanding of the safety and efficacy of the investigational medical product, restrict the availability of evidence-based treatment guidelines for vulnerable populations disproportionally burdened by disease, and delay access to innovative and potentially life-extending therapies.
CTTI interviewed 36 senior-level leaders at 20 organizations that conduct clinical trials to gather perspectives on strategies to support diversity and inclusion in clinical research. Based on these interviews and a 2-day meeting with 53 experts, CTTI identified four key action areas to implement sustainable, organizational-level practices: commitment, partnerships, accountability, and resources. To improve equitable access and increase diversity in clinical trial populations, CTTI suggests making diversity and inclusion in clinical trials an organizational priority and defining responsibility for these efforts, establishing and maintaining bi-directional community partnerships, and allocating organizational resources that support diversity and inclusion in clinical research. The CTTI Diversity Project Team is using the findings from this research to develop recommendations and a tool for institutions to use to initiate or enhance their diversity and inclusion efforts.
CTTI Holds Meeting to Discuss the Systemic Changes Needed to Increase Diversity in Clinical Trials
The Clinical Trials Transformation Initiative (CTTI) held a two-day multi-stakeholder expert meeting on Oct. 12 & 21 to discuss the systemic changes needed to ensure that U.S. clinical trials better meet the needs of diverse populations, including racial minorities, ethnic minorities, and women. At the meeting, leaders and key stakeholders from across the clinical trials ecosystem participated in an engaging forum, informative discussions, and lively breakout sessions that shed more light on new solutions for sharing information and ensuring sufficient resource allocation to diversity, equity, and inclusion initiatives.
Meeting attendees also identified some important themes and identified opportunities to increase diversity in clinical trials:
- The benefits are indisputable. Including a diverse population in clinical trials improves the quality of science, enhances patient trust, increases patient recruitment and retention, and improves clinical care for all patients.
- A culture shift is needed. Organizations need to ingrain diversity, equity, and inclusion initiatives into their portfolio-level strategy and within their overall mission. They should foster bi-directional community partnerships and directly engage patients in the design and planning of clinical trials and diversity efforts from the very beginning.
- This is a full group effort. Increasing diversity in clinical trials is a multi-stakeholder effort that will take all groups working together to achieve goals of clinical trial populations representing the populations who are affected by disease.
- There is important work ahead of us. Meeting attendees provided feedback on CTTI’s draft maturity model, helping to create a better public resource. Suggested additions included a focus on values and guidelines that are generalizable to a wide variety of stakeholders, not just industry stakeholders, and more guidance on how organizations can measure their progress through the maturity model.
CTTI is now using these findings – along with other research results and multi-stakeholder discussions – to develop recommendations and resources for release in early 2022. The project team may host additional webinars focusing on case studies and implementation of resources.

Clinical Trials Issues Related to COVID-19
Topics Included: Access to Clinical Trials, Ensuring Quality, Innovative Trials, Regulatory Submissions + Approvals
SHARE TO:
Overview
The COVID-19 pandemic caused unprecedented disruptions to nearly every aspect of clinical research.
To help, CTTI led several efforts -- including conducting surveys, holding webinars, and developing resources -- with the goal of helping the clinical trials ecosystem adapt and move forward during the pandemic, including:
- Two playbooks of best practices: "Best Practices for Conducting Trials During the COVID-19 Pandemic" and "Best Practices for Designing High-Quality, Diverse COVID-19 Trials".
- Recordings of six CTTI COVID-19 webinars are available:
- Identifying Best Practices for Conducting Clinical Trials with FDA's COVID-19 Guidance
- Designing High-Quality, Streamlined COVID-19 Trials
- Solutions for Switching to Remote and Virtual Visits
- Engaging Racial and Ethnic Minority Patient Populations during the Pandemic
- Using Master Protocol Studies for Effective COVID-19 Treatments
- The State of U.S. COVID-19 Treatment Clinical Trials
- A daily searchable spreadsheet of the COVID-19-related studies posted on ClinicalTrials.gov is also available.